Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 83.1% from a year ago
Other current liabilities stood at $17M at the end of Q1 FY2026, down 83.1% from a year earlier and down 90.7% from the prior quarter.
Context
- Other current liabilities amounted to 1.3% of total assets at the end of Q1 FY2026, down 6.3 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -83.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 183M USD
- Year-over-year change
- +109.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 183M | +109.2% |
| FY2024 | 2024-12-31 | 87.47M | -38.7% |
| FY2023 | 2023-12-31 | 142.79M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Liabilities vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's Mar 2026 other current liabilities of $17M is the 7th highest of the 11 companies compared; the peer median is $25.95M.
- Its year-over-year change of -83.1% is the lowest of 10, against a peer median of +62.1%.
- Other current liabilities amounts to 1.3% of total assets for RARE, versus a peer median of 5.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $946.11B | +427047.9% | -3.7% | 8.2% | |
| Jun 2026 | $473.08M | +31.8% | +17.1% | 14.6% | |
| Jun 2026 | $192.19M | +124.7% | +89.9% | 15.8% | |
| Mar 2026 | $119.74M | +1274.9% | +57.2% | 48.9% | |
| Mar 2026 | $28.31M | +79.8% | -6.0% | 3.6% | |
| Mar 2026 | $23.59M | -53.8% | -32.0% | 6.9% | |
| Mar 2026 | $17M | -83.1% | — | 1.3% | |
| Mar 2026 | $5.24M | +26.8% | +7.1% | 1.8% | |
| Mar 2026 | $2.62M | +21.1% | +26.3% | 1.3% | |
| Mar 2026 | $1.6M | +62.1% | -9.6% | 3.9% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RARE) | $25.95M | +62.1% | +7.1% | 5.4% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 307.58M | 132.94M | 213.58M | 173.73M | 434M |
| Short-term Investments | 432.61M | 614.82M | 363.63M | 436.3M | 259M |
| Net Receivables | 44.43M | 40.45M | 73.39M | 121.8M | 159M |
| Inventory | 16.23M | 26.77M | 33.97M | 45.01M | 52M |
| Other Current Assets | 55.75M | 68.93M | 47.62M | 40.29M | 47M |
| Total Current Assets | 856.6M | 883.9M | 732.18M | 817.12M | 951M |
| Property, Plant & Equipment (Net) | 176.18M | 259.73M | 290.57M | 265.93M | 267M |
| Goodwill | 44.41M | 44.41M | 44.41M | 44.41M | 44M |
| Intangible Assets | 130.79M | 160.11M | 166.27M | 178.31M | 176M |
| Long-term Investments | 293.86M | 148.97M | 199.9M | 135M | 59M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 20.56M | 48.34M | 57.69M | 62.68M | 35M |
| Total Non-current Assets | 665.79M | 661.55M | 758.83M | 686.33M | 581M |
| Total Assets | 1.52B | 1.55B | 1.49B | 1.5B | 1.53B |
| Account Payables | 17.14M | 43.27M | 42.11M | 38.76M | 31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 81M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.61M | 1.48M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 142.79M | 87.47M | 183M |
| Total Current Liabilities | 181.37M | 261.21M | 280.44M | 344.15M | 384M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.17B |
| Deferred Tax Liabilities | 33.31M | 31.67M | 30.06M | 30.06M | 30M |
| Deferred Revenue (Non-current) | 1.47M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 352.79M | 880.26M | 874.53M | 836.91M | (4M) |
| Total Non-current Liabilities | 418.47M | 931.74M | 935.16M | 897.01M | 1.22B |
| Total Liabilities | 599.84M | 1.19B | 1.22B | 1.24B | 1.61B |
| Common Stock | 69K | 70K | 82K | 92K | 0 |
| Retained Earnings | (2.07B) | (2.78B) | (3.39B) | (3.96B) | (4.53B) |
| Accumulated OCI | (1.4M) | (6.57M) | 647K | (643K) | 1M |
| Other Stockholders Equity | 0 | 0 | 432K | 3.59M | 8M |
| Minority Interest | 0 | 0 | 0 | 7M | 7M |
| Total Equity | 922.56M | 352.49M | 275.41M | 262.3M | (73M) |
| Total Debt | 41.97M | 31.59M | 43.17M | 40.34M | 1.28B |
| Net Debt | (265.61M) | (101.35M) | (170.42M) | (133.39M) | 842M |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.